Abstract:Psoriasis is a chronic inflammatory skin disease affecting millions of people worldwide, characterized by rapid proliferation of keratinocytes, immune cell infiltration, and systemic inflammation. Over time, treatment strategies have evolved significantly from traditional topical therapies and phototherapy to advanced systemic options such as biologics and, more recently, oral small molecule drugs. This review aims to provide an in-depth examination of current psoriasis therapies, with a focus on biologics, oral small molecules, and new and emerging treatments. Several classes of biologic therapies have received regulatory approval for psoriasis, including inhibitors of TNF-α, IL-12/23, IL-17, and IL-23. Biologics have transformed psoriasis care, offering improved disease management and quality of life for patients, with generally favorable safety profiles. However, challenges such as high cost, potential immunogenicity and complexity of administration have sparked interest in alternative treatment options. Oral small molecules, particularly Janus kinase (JAK) inhibitors, have gained attention for their efficacy and ease of use, being orally administered drugs. These drugs mark a shift in therapeutic paradigms by providing an oral option that precisely targets specific signaling pathways. In addition to existing therapies, this review also highlights emerging treatments that could shape the future of psoriasis care, including new small-molecule inhibitors. Early clinical trials suggest that these agents could improve treatment outcomes for psoriasis patients. Current research is increasingly focused on understanding disease recurrence, particularly the influence of tissue-resident memory T cells (TRMs). Avoiding the proliferation of these cells may be crucial in attenuating recurrence. In particular, interleukin-23 (IL-23), produced by CD301b+ cells, has been linked to stimulation of TRM cell proliferation in the skin. This finding highlights that IL-23 inhibitors and treatments targeting CD301b+ cells are promising strategies for maintaining remission and preventing relapse. In summary, the landscape of psoriasis treatments is advancing rapidly, with an increasing focus on personalized, patient-specific therapies. Research is expected to continue to refine and improve therapeutic approaches for this complex disease.

Newly discovered biologic agent used for psoriasis treatment

New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis

Small-molecule inhibitors of protein kinase C, the Janus kinases (JAK) pathway and phosphodiesterases in the treatment of psoriasis

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

New and emerging oral therapies for psoriasis

Promising new treatments for psoriasis

Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?

Current therapeutic overview and future perspectives regarding the treatment of psoriasis

New Treatment Addressing the Pathogenesis of Psoriasis

Biologic Medications for the Treatment of Psoriasis - Main Groups and Dosing System

Small Molecules in the Management of Psoriasis and Psoriatic Arthritis

New therapeutic options in psoriasis

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians

Chinese Experts Consensus on Biologic Therapy for Psoriasis #

Advances in psoriasis research: From pathogenesis to therapeutics

Breakthrough Opportunities of Nanotheranostics in Psoriasis: From Pathogenesis to Management Strategy

Novel Biologics in Treatment of Psoriatic Arthritis

Targeting VEGF/VEGFR in the Treatment of Psoriasis.

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents

Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part I